AINDEX
Markets

Corvus Pharmaceuticals, Inc. (CRVS)

CRVSNASDAQ-GMBiotechnology: Pharmaceutical Preparations

$10.64

-0.0700 (-0.65%) today

At the close, Nov 13, 4:00 PM ET. Pre-market $12.00 +12.78%

-4.49% 1D
Market cap
$1.01bn
P/E
–
EPS, last 4 quarters
$-0.7100
Dividend yield
–
Day range
–
52-week range
$6.39 to $26.95
Average volume
–
Previous close
$10.71

Analysts

4 covering

Buy4 buy, 0 hold, 0 sell

Targets a year out average $28.75, +170.2% from here

$27.00now $10.64$33.00

Earnings

next estimate $-0.2300

Next report

Dec 2025

-7.1%

Mar 2026

-7.1%

Jun 2026

-11.8%

Sep 2026

-4.8%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue––––
Gross profit––––
Operating income-$12.22m-$14.88m-$19.30m-$21.36m
Net income-$12.32m-$13.69m-$17.96m-$20.34m

News

8 latest

The company

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registrational Phase 3 clinical trial for relapsed/refractory peripheral T cell lymphoma (PTCL), a Phase 2 clinical trial for the treatment of atopic dermatitis, and a Phase 1b clinical trial for hidradenitis suppurativa. Its other clinical-stage candidates are being developed for a variety of cancer indications.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GM
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.

Corvus Pharmaceuticals, Inc. (CRVS) price, chart and news · AINDEX